← Leaderboards
Kim L Isaacs
University Of North Carolina Chapel Hill
$2,243,938
Attributed
$2,243,938
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.6K · FY2007–08$10K$7.5K$5K$2.5K$0
'07
'08
Funding mix
By agency
NIH$2,243,938 · 6
By mechanism
M01$2,243,938 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Douglas A Drossman$8,090,089
- Mark J Kutcher$3,795,959
- Pauline K Lund$8,967,376
- William E Whitehead$15,555,686
- Mary A Dooley$3,689,855
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationCrohn'S DiseaseClinical ResearchHuman SubjectGastrointestinal Disorder ChemotherapyDrug Screening /EvaluationSteroidsAzathioprineQuinolineIntravenous AdministrationAntiulcer DrugAntirheumatic AgentsChemotherapyGastrointestinal AgentsHormone TherapyImmunomodulatorsQuality Of LifeQuestionnairesDrug Adverse EffectDrug Administration Rate /DurationInterleukin 10Longitudinal Human StudyDoseBase
Grant awards (21)
CLINICAL TRIAL: MULTI-SITE TRIAL OF AZATHIOPRINE DOSING IN CROHN'S DISEASE$2,066
M01 · FY2008 · RR · contact PI
MULTI-SITE TRIAL OF AZATHIOPRINE DOSING IN CROHN'S DISEASE$5,627
M01 · FY2007 · RR · contact PI
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$190,747
M01 · FY2002 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$190,747
M01 · FY2002 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$294,555
M01 · FY2001 · RR
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$294,555
M01 · FY2001 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$190,747
M01 · FY2001 · RR
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$190,747
M01 · FY2001 · RR
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$294,555
M01 · FY2000 · RR
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$294,555
M01 · FY2000 · RR
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$294,555
M01 · FY2000 · RR
AZATHIOPRINE LOADING TO DECREASE RESPONSE TIME IN CROHN'S DISEASE$241
M01 · FY2000 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$241
M01 · FY2000 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$0
M01 · FY2000 · RR
SUBCUTANEOUS HUIL-10 (SCH 5200) IN CROHN'S DISEASE$0
M01 · FY2000 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$0
M01 · FY2000 · RR
ANTI-TNFALPHA MONOCLONAL ANTIBODY IN CROHN'DISEASE$0
M01 · FY2000 · RR
TAK 603/A 165646 IN PATIENTS W/ CROHNS DISEASE$0
M01 · FY2000 · RR
SUBCUTANEOUS HUIL-10 (SCH 5200) IN CROHN'S DISEASE$0
M01 · FY2000 · RR
SUBCUTANEOUS HUIL-10 (SCH 5200) IN CROHN'S DISEASE$0
M01 · FY2000 · RR
SUBCUTANEOUS HUIL-10 (SCH 5200) IN CROHN'S DISEASE$0
M01 · FY2000 · RR